Printer Friendly

LEDERLE LABORATORIES ANNOUNCES NEW SALES FORCE: ADVANTUS PHARMACEUTICALS

 LEDERLE LABORATORIES ANNOUNCES NEW SALES FORCE:
 ADVANTUS PHARMACEUTICALS
 WAYNE, N.J., March 10 /PRNewswire/ -- Lederle Laboratories, a division of American Cyanamid Company (NYSE: ACY), has announced the formation of Advantus Pharmaceuticals, a new sales force created to better serve the needs of physicians and pharmacists.
 The addition of Advantus Pharmaceuticals increases the size of Lederle's sales force by 50 percent. The new sales force and the Lederle Laboratories sales force will concentrate on different therapeutic areas in the Lederle product line. This expansion and reorganization will allow highly specialized representatives to communicate more effectively and respond to the individual, growing needs of family physicians and retail pharmacists.
 "Advantus Pharmaceuticals is a new, sharply focused approach to delivering Lederle's growing line of products and services," said David R. Bethune, president of Lederle Laboratories. "This significant change within our company has been implemented to provide physicians and pharmacists with the improved professional service that their dynamic practices and businesses demand."
 "Lederle is in a very positive growth phase with exciting new product opportunities, such as our new nicotine transdermal system, ProStep(TM)," Bethune added. "The creation of Advantus Pharmaceuticals will enable Lederle to become an even stronger force in a highly competitive marketplace."
 Lederle Laboratories is a research-intensive organization that manufactures and markets a broad range of products worldwide, including ethical pharmaceuticals, vaccines, generics and vitamins/nutritionals.
 -0- 3/10/92
 /CONTACT: Jeff Hoyak of Lederle Laboratories, 201-831-4619/
 (ACY) CO: Lederle Laboratories; American Cyanamid Company ST: New Jersey IN: MTC SU:


KD-KW -- NY002 -- 6811 03/10/92 11:00 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 10, 1992
Words:258
Previous Article:ANALOG DEVICES OUTLINES PLAN TO RESTORE GROWTH AND PROFITABILITY
Next Article:FIRST FEDERAL SAVINGS AND LOAN OF CHARLOTTE INTRODUCES FIRST FEDERAL REVERSE MORTGAGE
Topics:


Related Articles
DAVID R. BETHUNE NAMED FOUNDING TRUSTEE OF NEWLY FORMED AMERICAN CANCER SOCIETY FOUNDATION
MEDIMMUNE AND CYANAMID TO ENTER FOUR DRUG, $30 MILLION STRATEGIC ALLIANCE
LEDERLE STANDARD PRODUCTS ANNOUNCES AVAILABILITY OF ALPRAZOLAM TABLETS, ONE OF THE FIRST GENERIC VESIONS OF TOP-SELLING ANTI-ANXIETY DRUG
MEDIMMUNE AND CYANAMID SIGN FOUR DRUG, $30 MILLION STRATEGIC ALLIANCE; MEDIMMUNE AND CYANAMID TO BEGIN SELLING ZOSYN TODAY
LEDERLE AND P&G TO CO-PROMOTE ZIAC, FIRST ANTIHYPERTENSIVE DEVELOPED SPECIFICALLY TO ADDRESS DOSE-RELATED SIDE EFFECTS
IMMUNEX ELECTS EDWARD V. FRITZKY CHAIRMAN AND CHIEF EXECUTIVE OFFICER
MARY E. PETIT JOINS BARR LABORATORIES AS VICE PRESIDENT OF QUALITY
TIMOTHY P. CATLETT NAMED VP, SALES & MARKETING FOR BARR LABORATORIES
PHARMACEUTICAL RESOURCES, INC. ANNOUNCES APPOINTMENT OF DANIEL H. GOLD, PH.D. AS VICE PRESIDENT, QUALITY ASSURANCE
ESI Lederle Launches Etodolac

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters